Heron Therapeutics Analyst Ratings
Heron Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/15/2023 | 231.13% | Needham | → $5 | Reiterates | Buy → Buy |
| 07/25/2023 | 231.13% | Needham | $6 → $5 | Maintains | Buy |
| 05/12/2023 | 297.35% | Needham | $7 → $6 | Maintains | Buy |
| 04/21/2023 | 363.58% | Needham | → $7 | Reiterates | → Buy |
| 03/24/2023 | 562.25% | Evercore ISI Group | $15 → $10 | Maintains | Outperform |
| 03/24/2023 | 363.58% | Needham | $8 → $7 | Maintains | Buy |
| 11/09/2022 | 429.8% | Needham | $10 → $8 | Maintains | Buy |
| 06/30/2022 | 562.25% | Needham | $14 → $10 | Maintains | Buy |
| 05/10/2022 | 827.15% | Needham | $16 → $14 | Maintains | Buy |
| 12/02/2020 | 1489.4% | SVB Leerink | $21 → $24 | Maintains | Outperform |
| 05/27/2020 | 1489.4% | Guggenheim | → $24 | Initiates Coverage On | → Buy |
| 03/02/2020 | 2813.91% | Needham | $48 → $44 | Maintains | Buy |
| 02/20/2020 | 3078.81% | Needham | $50 → $48 | Maintains | Buy |
| 10/03/2019 | 2019.21% | JMP Securities | $38 → $32 | Reiterates | → Market Outperform |
| 09/14/2018 | 3542.38% | Stifel | → $55 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年08月15日 | 231.13% | 李约瑟 | →$5 | 重申 | 购买→购买 |
| 07/25/2023 | 231.13% | 李约瑟 | $6→$5 | 维护 | 买 |
| 2023年05月12日 | 297.35% | 李约瑟 | $7→$6 | 维护 | 买 |
| 04/21/2023 | 363.58% | 李约瑟 | →$7 | 重申 | →购买 |
| 03/24/2023 | 562.25% | Evercore ISI集团 | $15→$10 | 维护 | 跑赢大盘 |
| 03/24/2023 | 363.58% | 李约瑟 | $8→$7 | 维护 | 买 |
| 11/09/2022 | 429.8% | 李约瑟 | $10→$8 | 维护 | 买 |
| 2022/06/30 | 562.25% | 李约瑟 | $14→$10 | 维护 | 买 |
| 2022年05月10日 | 827.15% | 李约瑟 | $16→$14 | 维护 | 买 |
| 12/02/2020 | 1489.4% | SVB Leerink | $21→$24 | 维护 | 跑赢大盘 |
| 05/27/2020 | 1489.4% | 古根海姆 | →$24 | 开始承保 | →购买 |
| 03/02/2020 | 2813.91% | 李约瑟 | $48→$44 | 维护 | 买 |
| 02/20/2020 | 3078.81% | 李约瑟 | $50→$48 | 维护 | 买 |
| 2019年10月03日 | 2019.21% | JMP证券 | $38→$32 | 重申 | →市场跑赢大盘 |
| 2018年09月14日 | 3542.38% | Stifel | →$55 | 开始承保 | →购买 |
What is the target price for Heron Therapeutics (HRTX)?
苍鹭治疗公司(HRTX)的目标价格是多少？
The latest price target for Heron Therapeutics (NASDAQ: HRTX) was reported by Needham on August 15, 2023. The analyst firm set a price target for $5.00 expecting HRTX to rise to within 12 months (a possible 231.13% upside). 7 analyst firms have reported ratings in the last year.
Needham于2023年8月15日报道了苍鹭治疗公司(纳斯达克代码：HRTX)的最新目标价。这家分析公司将目标价定为5美元，预计HRTX将在12个月内上涨至(可能上涨231.13%)。去年有7家分析公司公布了评级。
What is the most recent analyst rating for Heron Therapeutics (HRTX)?
苍鹭治疗公司(HRTX)的最新分析师评级是多少？
The latest analyst rating for Heron Therapeutics (NASDAQ: HRTX) was provided by Needham, and Heron Therapeutics reiterated their buy rating.
Needham提供了对苍鹭治疗公司(纳斯达克代码：HRTX)的最新分析师评级，苍鹭治疗公司重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for Heron Therapeutics (HRTX)?
苍鹭治疗公司(HRTX)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Heron Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Heron Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与苍鹭治疗公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。苍鹭治疗的最后一次评级是在2023年8月15日提交的，所以你应该预计下一次评级将在2024年8月15日左右提供。
Is the Analyst Rating Heron Therapeutics (HRTX) correct?
分析师对苍鹭治疗公司(HRTX)的评级正确吗？
While ratings are subjective and will change, the latest Heron Therapeutics (HRTX) rating was a reiterated with a price target of $0.00 to $5.00. The current price Heron Therapeutics (HRTX) is trading at is $1.51, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的苍鹭治疗公司(HRTX)的评级被重申，目标价在0.00美元到5.00美元之间。苍鹭治疗公司(HRTX)目前的交易价格为1.51美元，在分析师的预测范围内。